Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius Medical Care AG & Co. KGaA

Investor Presentation • Jan 11, 2011

165_ip_2011-01-11_81fe29e4-901d-45d9-b367-5bf53938ad43.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Commerzbank German Investment Seminar

New York, January 10, 2011

Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

1. Business Update

2. Financials & Outlook

3. Growth Strategy & Summary

Excellent quarter and fully on track for full-year targets

Q
3
2
0
0
9		 Q
3
2
0
1
0		 G
h
t
r
o
w
R
e
v
e
n
u
e		 \$
2
8
8
9
m
,		 \$
3
0
5
8
m
,		 6
%
i
N
t
e
n
c
o
m
e
i
bu
b
le
F
M
C
A
G
&
Co
K
Ga
A
t
tr
ta
to
a		 \$
2
2
5
m		 \$
2
4
8
m		 %
1
0
E
i
h
a
r
n
n
g
s
p
e
r
s
a
r
e		 \$
0
6
7		 \$
0
8
2		 9
%
  • •Strong revenue growth at 7% at constant currency and 6% organic
  • •Very good EBIT-margin development
  • •Resulting in net income growth of 10%

Total revenue increased by 7%cc to \$3,058 m

Q3 Dialysis Services Global

Continued excellent revenue growth of 9%cc

\$
S
U
i
l
l
i
m
o
n
s		 Q
3
2
0
0
9		 Q
3
2
0
1
0		 G
t
h
r
o
w		 c
c
i
N
h
A
t
o
r
m
e
r
c
a		 1
7
4
1
,		 1
8
6
3
,		 %
7
i
I
l
t
t
n
e
r
n
a
o
n
a		 4
0
6		 4
5
8		 %
1
3		 %
1
7
T
l
t
o
a		 2
1
4
7
,		 2
3
2
1
,		 8
%		 9
%
  • •Very good organic treatment growth of 4.7% globally
  • •Continued strong revenue per treatment development
  • •Treating 210,191 patients in 2,716 clinics

cc = constant currency

Continued improvement of patient outcomes

N
h
A
t
o
r
m		 i
(
U
S
)
e
r
c
a		 E
M		 E
A
%
f
i
t
t
o
p
a
e
n
s		 Q
3
2
0
0
9		 Q
3
2
0
1
0		 Q
3
2
0
0
9		 Q
3
2
0
1
0
K
/
V
1
2
t
≥		 9
6
%		 9
6
%		 9
%
5		 5
9
%
1
0
1
2
/
H
l
b
i
d
l
e
m
o
g
o
n
g
=
-		 6
%
4		 6
9
%		 3
%
5		 5
4
%
H
l
b
i
1
0
1
3
/
d
l
e
m
o
g
o
n
g
=
-		 8
7
%		 8
8
%		 7
6
%		 6
%
7
A
l
b
i
3
/
d
l
5
≥
u
m
n
g		 8
2
%		 8
2
%		 8
%
7		 8
6
%
P
h
h
3
5
5
5
/
d
l
t
o
s
p
a
e
m
g
-		 5
4
%		 5
%
7		 6
0
%		 6
1
%
H
i
t
l
i
t
i
d
o
s
p
a
a
o
n
a
s
z
y		 1
0
0		 *
9
8		 8
7		 9
4

The hospitalization rates for the US reflects adoption of CMS policy *

Q3 Dialysis Services Global

Further improved performance in all key metrics

Q
3
2
0
1
0		 T
l
t
o
a		 N
h
A
i
t
o
r
m
e
r
c
a		 I
i
l
t
t
n
e
r
n
a
o
n
a
O
i
t
h
r
g
a
n
c
r
e
e
n
e
g
r
o
v
u
w		 %
7		 %
7		 %
6
S
k
h
t
t
t
t
t
a
m
e
m
a
r
e
r
e
a
m
e
n
g
r
o
w		 4
7
%		 4
3
%		 5
6
%
R
t
t
t
e
e
n
e
p
e
r
r
e
a
m
e
n
v
u		 *
\$
3
5
1		 \$
1
6
5
c
c
S
3
0,
2
0
1
0
t
b
e
p
e
m
e
r
N
b
f
l
i
i
m
e
r
o
c
n
c
s
u		 2
7
1
6
,		 1
8
0
9
,		 9
0
7
G
h
t
r
o
w		 8
%		 3
%		 1
9
%
D
e
n
o
v
o
s		 2
7		 2
4		 3
0

* including Mexico

Q3 Revenue per treatment US

Stable reimbursement environment

Product growth in North America impacted by mix shift

\$
U
S
i
l
l
i
m
o
n
s		 Q
3
2
0
0
9		 Q
3
2
0
1
0		 G
h
t
r
o
w		 c
c
T
l
t
o
a
r
e
e
n
e
v
u
(
inc
l.
in
ter
l re
)
na
ve
nu
e		 1
0
0
3
,		 1
0
1
8
,		 2
%		 4
%
E
l
t
x
e
r
n
a
r
e
v
e
n
u
e		 4
2
7		 7
3
7		 1
%
-		 3
%
N
h
A
i
t
o
r
m
e
r
c
a		 2
0
9		 2
0
8		 0
%
I
t
t
i
l
n
e
r
n
a
o
n
a		 5
3
3		 5
2
9		 %
1
-		 %
4

cc = constant currency

Q3 I 9M Summary

Product Launches

1. Business Update

2. Financials & Outlook

3. Growth Strategy & Summary

9M Profit & Loss

\$
U
S
i
l
l
i
m
o
n
s		 9
M
2
0
0
9		 M
9
2
0
1
0		 G
h
t
r
o
w
N
t
e
r
e
v
e
n
u
e		 8
2
1
2
,		 8
8
8
6
,		 *
8
%
O
(
)
i
i
E
B
I
T
t
p
e
r
a
n
g
n
c
o
m
e		 1
2
6
5
,		 1
3
8
5
,		 1
0
%
%
E
B
I
T
i
i
m
a
r
g
n
n		 1
5
4		 1
5
6
I
t
t
t
n
e
r
e
s
e
x
p
e
n
s
e,
n
e		 2
2
5		 2
0
6
I
b
f
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 1
0
4
0
,		 1
1
9
7
,		 %
1
3
I
t
n
c
o
m
e
a
x
e
x
p
e
n
s
e		 3
4
5		 4
1
0
T
t
a
x
r
a
e		 3
3
%		 3
5
%
N
l
l
i
i
t
t
t
o
n-
c
o
n
r
o
n
g
n
e
r
e
s		 0
5		 6
2
N
i
t
e
n
c
o
m
e
C
G
&
Co
Ga
t
tr
i
bu
ta
b
le
to
F
M
A
K
A
a		 6
4
5		 0
7
7		 %
1
0

* 8% growth at constant currency, 6% organic growth

Operating cash flow above \$ 1 billion and at 12% of revenue

\$
U
S
i
l
l
i
m
o
n
s		 9
M
2
0
0
9		 9
M
2
0
1
0		 G
t
h
r
o
w
1)
O
i
h
f
l
t
p
e
r
a
n
g
c
a
s
o
w		 8
8
0		 1
0
2
7
,
1
2
%
f r
o
ev
en
ue		 1
%
7
1)
C
i
l
d
i
t
t
t
a
p
a
e
x
p
e
n
u
r
e
s
n
e
,		 (
3
8
8
)		 (
)
3
3
9
F
h
f
l
r
e
e
c
a
s
o
w		 4
9
2		 6
8
8
8
%
f r
o
ev
en
ue		 %
4
0
1)
2)
A
i
i
i
t
f
d
i
i
c
q
u
s
o
n
s
t
t
t
n
e
o
v
e
s
u
r
e
s
,		 (
)
1
0
7		 (
)
2
3
9
1)
2)
f
F
h
l
f
t
i
i
t
i
r
e
e
c
a
s
o
w
a
e
r
a
c
q
s
o
n
s
u
,		 3
8
5		 4
4
9

1) A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

2) Does not include a \$131 m cash out for a short-term bank deposit in Q2 2010 and a cash repayment in form of an inter-company loan of \$ 50 m in Q2 2009

2010 Guidance – Outlook improved

US\$ millions Guidance
Net revenue > \$12,000
Net income
improved
attributable to FMC AG & Co. KGaA		 \$960 - 980
Leverage ratio (Debt/EBITDA) < 2.5
Capital expenditures $$550 - 650$
Acquisitions up to \$500

World Leader in Dialysis Services

EMEA

* patients including managed clinics

North America

Market Position by Major Product Groups

R
k
1
a
n		 R
k
2
a
n		 R
k
3
a
n
i
D
l
a
e
r
s
y
z		 F
M
E		 G
b
a
m
r
o		 N
i
p
r
o
D
i
l
i
h
i
a
y
s
s
m
a
c
n
e
s		 F
M
E		 G
b
a
m
r
o		 N
i
k
k
i
s
o
H
d
i
l
i
t
t
e
m
o
a
s
s
c
o
n
c
e
n
r
a
e
s
y		 F
M
E		 F
s
o
u		 G
b
a
m
r
o
B
l
d
l
i
o
o
n
e
s		 F
M
E		 G
b
a
m
r
o		 K
i
a
w
a
s
u
m
i
i
i
P
l
d
l
d
t
t
e
r
o
n
e
a
a
s
s
p
r
o
c
s
y
u		 B
t
a
e
r
x		 F
M
E		 P
i
s
a

Produced more than ~85,000,000 Dialyzers in 2009

Development of Dialysis Patient Population

  • Renal failure persists worldwide
  • Dialysis is the primary treatment modality on a global scale
  • The number of global dialysis patients is expected to double by 2020

Market Opportunity by Region

FME's Products and Services by Region

Continued Growth Opportunities

Rationale for ESRD Integrated Care

L
d
h
i
e
a
e
r
s
p		 M
i
i
l
b
l
l
d
h
i
i
i
t
t
a
n
a
n
o
u
r
g
o
a
e
a
e
r
s
p
p
o
s
o
n
•
C
i
h
h
f
f
h
d
i
l
i
i
d
t
t
t
t
t
t
o
n
n
u
e
o
s
a
p
e
e
u
u
r
e
o
e
a
y
s
s
n
u
s
r
y
•
Q
l
i
t
u
a
y		 M
i
i
i
l
i
i
d
d
i
t
t
t
a
n
a
n
s
p
e
r
o
r
q
a
n
p
r
o
c
s
a
n
s
e
r
c
e
s
u
u
y
u
v
•
G
h
t
r
o
w		 B
f
i
f
d
i
i
t
t
t
e
n
e
r
o
m
p
r
o
u
c
n
n
o
v
a
o
n
s
•
f
T
k
i
i
i
l
h
i
l
t
t
t
t
t
t
t
a
e
o
p
p
o
r
n
o
n
e
r
n
a
o
n
a
g
r
o
p
o
e
n
a
u
y
w
•
f
f
i
I
d
h
t
t
n
r
o
c
e
n
e
e
r
a
p
o
e
r
n
g
s
u
w
y
•
C
i
i
i
f
i
h
l
d
d
t
t
t
o
n
n
e
o
r
o
n
a
e
p
a
n
s
o
n
o
s
e
r
c
e
a
n
p
r
o
c
r
a
n
g
e
u
z
x
v
u
•
i
i
F
l
n
a
n
c
a		 C
l
d
d
i
t
t
o
n
r
o
c
o
s
a
n
s
p
e
n
n
g
•
S
k
i
i
i
i
t
t
t
t
t
t
t
e
e
a
r
a
c
e
n
e
s
m
e
n
o
p
p
o
r
n
e
s
v
v
u
•
C
i
f
i
b
l
h
t
t
t
t
o
n
n
u
e
p
r
o
a
e
g
r
o
w
m
o
m
e
n
u
m
•

Thank you for your interest in Fresenius Medical Care

Reconciliation of non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measure

All figures are in \$ millions

D
b
t
e		 Q
3
2
0
1
0		 F
Y
2
0
0
9		 F
Y
2
0
0
8		 F
Y
2
0
0
7
S
ing
(
inc
/
)
ho
t-
te
bo
l.
A
R
r
rm
rro
w
s
p
ro
g
ra
m		 6
2
3		 3
1
6		 6
8
4		 2
1
7
S
ho
t-
ter
bo
ing
fro
la
te
d p
t
ies
+
r
m
rro
s
m
re
ar
w		 1
0		 1
0		 1 2
Cu
t p
t
ion
f
lon
ter
de
b
t a
d c
i
ta
l
lea
b
l
ig
t
ion
+
rre
n
or
o
g-
m
n
ap
se
o
a
s		 1
5
8		 1
5
8		 4
5
5		 8
5
Cu
ion
f
fer
d s
i
ies
t p
t
tru
t p
t
+
rre
n
or
o
s
re
re
ec
ur		 6
3
4		 6
7
0
Lo
de
b
d c
i
l
lea
b
l
ig
ion
-te
t a
ta
t
+
ng
rm
n
ap
se
o
a
s,
les
t p
t
ion
s c
urr
en
or		 3
1
1
4,		 2
8
4,
4		 3,
9
5
7		 0
0
4,
4
Tr
t p
fer
d s
i
t
ies
+
us
re
re
ec
ur		 - 6
5
6		 6
4
1		 6
6
4
To
l
de
b
ta
t
=		 5,
7
3
6		 5,
5
6
8		 5,
7
3
8		 5,
6
4
2
E
B
I
T
D
A		 Q
3
2
0
1
0		 1)
F
Y
2
0
0
9		 F
Y
2
0
0
8		 F
Y
2
0
0
7
La
lve
hs
ing
inc
(
E
B
I
T
)
t
tw
t
t
s
e
m
on
o
p
er
a
om
e		 1,
8
7
6		 1,
6
9
7		 1,
6
7
2		 1,
5
8
0
La
t
tw
lve
t
hs
de
ia
t
ion
d a
t
iza
t
ion
+
s
e
m
on
p
rec
an
mo
r		 4
9
2		 4
4
3		 4
1
6		 3
6
3
No
h c
ha
+
n-c
as
rg
es		 4
8		 4
8		 4
4		 4
1
E
B
I
T
D
A
(
l
ize
d
)
an
nu
a
=		 2,
4
1
6		 2,
1
8
8		 2,
1
3
2		 1,
9
8
4
C
(
)
i
l
d
i
t
t
t
a
p
a
e
p
e
n
r
e
n
e
x
u		 9
M
2
0
1
0		 9
M
2
0
0
9		 Q
3
2
0
1
0		 Q
3
2
0
0
9
Pu
ha
f p
ty,
lan
t a
d e
ip
t
rc
se
o
ro
p
er
p
n
q
u
me
n		 (
3
5
0
)		 (
3
9
8
)		 (
1
2
3
)		 (
1
4
5
)
Pr
ds
fro
le
f p
ty,
lan
t a
d e
ip
t
oc
ee
m
sa
o
ro
p
er
p
n
q
u
me
n
-		 1
1		 1
0		 2 6
Ca
(
)
i
l e
d
i
ta
tu
t
p
xp
en
re
ne
=		 (
)
3
3
9		 (
)
3
8
8		 (
)
1
2
1		 (
)
1
3
9

1) Excluding restructuring costs and in-process R&D

Attachment II

Reconciliation of non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measure

E
l
R
t
x
e
r
n
a
e
v
e
n
u
e

All figures are in \$ millions

(
)
A
i
i
i
t
t
c
q
s
o
n
s
n
e
u		 9
M
2
0
1
0		 9
M
2
0
0
9		 Q
3
2
0
1
0		 Q
3
2
0
0
9
Ac
is
i
t
ion
d
inv
tm
t a
d
t p
ha
f
in
ta
i
b
le
ts
q
u
s a
n
es
en
n
ne
ur
c
se
s o
ng
as
se		 (
3
7
8
)		 (
1
0
9
)		 (
8
8
)		 (
2
7
)
fro
Pr
ds
d
ive
t
i
tu
oc
ee
m
s
re
s		 8 2
5		 1 1
Ac
is
i
ion
d
inv
f
d
ive
i
t
tm
ts
t o
t
tu
q
s a
n
es
en
ne
s
re
s
u
,		 (
3
0
)
7		 (
)
5
7		 (
8
)
7		 (
2
6
)
Inv
f r
tm
t,
t o
ts
es
en
ne
ep
ay
me
n		 1
3
1		 (
5
0
)		 - -
Ac
is
i
ion
f
d
ive
i
t
t o
t
tu
q
s,
ne
s
re
s
u		 (
2
3
9
)		 (
1
0
7
)		 (
8
7
)		 (
2
6
)

cc = constant currency

Q
3
2
0
1
0		 C
l
i
i
n
c
s		 P
i
t
t
a
e
n
s		 T
t
t
r
e
a
m
e
n
s
(
in
i
l
l
ion
)
m
s
T
t
l
o
a		 2
7
1
6
,		 2
1
0
1
9
1
,		 2
3
4
G
t
h
r
o
w		 %
8
+		 %
9
+		 %
7
+
N
t
h
A
i
o
r
m
e
r
c
a		 1
8
0
9
,		 1
3
6
5
7
4
,		 1
5
5
G
h
t
r
o
w		 3
%
+		 4
%
+		 %
5
+
I
i
l
t
t
n
e
r
n
a
o
n
a		 9
0
7		 7
4
4
4
5
,		 7
9
G
t
h
r
o
w		 %
1
9
+		 %
2
0
+		 %
1
1
+
E
u
r
o
p
e		 4
8
2		 3
6,
8
7
1		 4
0
L
t
i
A
i
a
n
m
e
r
c
a		 1
9
1		 2
1,
9
3
4		 2
5
A
i
P
i
f
i
s
a-
a
c
c		 2
3
4		 1
5,
6
4
0		 1.
4

Operating Margin Development

9M 2010 Operating Margin Development

9
M
2
0
0
9		 9
M
2
0
1
0		 G
t
h
r
o
w
R
e
e
n
e
v
u		 \$
8
2
1
2
m
,		 \$
8
8
8
6
m
,		 %
8
N
i
t
e
n
c
o
m
e
C
G
&
Co
Ga
t
tr
i
bu
ta
b
le
to
F
M
A
K
A
a		 \$
5
6
4
m		 \$
7
0
7
m		 1
0
%
i
E
h
a
r
n
n
g
s
p
e
r
s
a
r
e		 \$
2
1
6		 \$
2
3
5		 %
9
  • •Strong revenue growth at 8% at constant currency and 6% organic
  • •Continued excellent cash flow development

9M Revenue

Total revenue increased by 8%cc to \$8,886 m

9M Dialysis Services Global

Excellent revenue growth globally

\$
S
U
i
l
l
i
m
o
n
s		 9
M
2
0
0
9		 9
M
2
0
1
0		 G
t
h
r
o
w		 c
c
i
N
h
A
t
o
r
m
e
r
c
a		 4
9
9
5
,		 5
4
4
1
,		 %
9
I
i
l
t
t
n
e
r
n
a
o
n
a		 1
1
2
9
,		 1
2
5
7
,		 1
3
%		 1
2
%
T
l
t
o
a		 6
1
2
4
,		 6
7
1
6
,		 1
0
%		 9
%
  • •Good organic treatment growth of 4.4% globally
  • •Continued strong revenue per treatment development

cc = constant currency

Total revenue growth year to date on target

\$
U
S
i
l
l
i
m
o
n
s		 9
M
2
0
0
9		 M
9
2
0
1
0		 G
h
t
r
o
w		 c
c
T
l
t
o
a
r
e
e
n
e
v
u
(
inc
l.
in
ter
l re
)
na
ve
nu
e		 2
8
1
6
,		 2
9
8
0
,		 6
%		 %
5
E
l
t
x
e
r
n
a
r
e
v
e
n
u
e		 2
0
8
8
,		 2
1
0
7
,		 4
%		 3
%
N
t
h
A
i
o
r
m
e
r
c
a		 6
0
5		 6
1
7		 2
%
I
t
t
i
l
n
e
r
n
a
o
n
a		 1
4
8
3
,		 1
5
5
3
,		 %
5		 %
4

cc = constant currency

Q3 Profit & Loss

\$
U
S
i
l
l
i
m
o
n
s		 Q
3
2
0
0
9		 Q
3
2
0
1
0		 G
h
t
r
o
w
N
t
e
r
e
v
e
n
u
e		 2
8
8
9
,		 5
3
0
8
,		 *
6
%
O
(
)
i
i
E
B
I
T
t
p
e
r
a
n
g
n
c
o
m
e		 1
4
5		 4
9
3		 9
%
%
E
B
I
T
i
i
m
a
r
g
n
n		 1
5
6		 1
6
1
I
t
t
t
n
e
r
e
s
e
x
p
e
n
s
e,
n
e		 7
5		 0
7
I
b
f
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 3
7
6		 4
2
3		 %
1
2
I
t
n
c
o
m
e
a
x
e
x
p
e
n
s
e		 1
3
1		 1
5
3
T
t
a
x
r
a
e		 3
5
%		 3
6
%
N
l
l
i
i
t
t
t
o
n-
c
o
n
r
o
n
g
n
e
r
e
s		 2
0		 2
2
N
i
t
e
n
c
o
m
e
C
G
&
Co
Ga
t
tr
i
bu
ta
b
le
to
F
M
A
K
A
a		 2
2
5		 2
4
8		 %
1
0

* 7% growth at constant currency, 6% organic growth

Days Sales Outstanding (DSO)

Continued excellent cash collection

Very Strong operating cash flow performance

\$
U
S
i
l
l
i
m
o
n
s		 Q
3
2
0
0
9		 Q
3
2
0
1
0		 G
t
h
r
o
w
1)
O
f
i
h
l
t
p
e
r
a
n
g
c
a
s
o
w		 4
4
3		 3
8
4
1
3
%
f r
o
ev
en
ue		 1
3
%
-
1)
C
i
l
d
i
t
t
a
p
a
e
p
e
n
r
e
s
t
x
u
n
e
,		 (
1
3
9
)		 (
)
1
2
1
F
h
f
l
r
e
e
c
a
s
o
w		 3
0
4		 2
6
3
9
%
f r
o
ev
en
ue		 %
1
4
-
1)
A
i
i
t
i
t
f
d
i
t
i
t
c
q
u
s
o
n
s
n
e
o
e
s
r
e
s
v
u
,		 (
2
6
)		 (
)
8
7
1)
F
h
f
l
f
t
i
i
t
i
r
e
e
c
a
s
o
w
a
e
r
a
c
q
u
s
o
n
s
,		 2
7
8		 1
7
6

1) A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

Q3 Debt and EBITDA Development

Debt/EBITDA ratio improved further

* including non-cash charges and in 2007 excluding restructuring costs, in-process R&D and gain from the sale of dialysis clinics. A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

Industry's only vertically integrated provider

Commerzbank GIS 2011 © 2011Fresenius Medical Care AG & Co. KGaA

Global Strategy - Services – Areas to Improve Dialysis Outcomes

F
Y
R
l
2
0
1
0
t
e
s
u
s		 – A
l
M
i
F
b
2
3,
2
0
1
1
t
t
n
a
y
s
e
e
n
g
e
r
u
a
r
y
,
Q
1
2
0
1
1
R
l
t
e
s
s
u		 – C
f
C
l
l,
M
4,
2
0
1
1
o
n
e
r
e
n
c
e
a
a
y
Q
R
l
2
2
0
1
1
t
e
s
s
u		 – C
f
C
l
l,
A
3,
2
0
1
1
t
o
n
e
r
e
n
c
e
a
g
s
u
u
Q
3
2
0
1
1
R
l
t
e
s
u
s		 – C
f
C
l
l,
N
b
2,
2
0
1
1
o
n
e
r
e
n
c
e
a
o
v
e
m
e
r

Fresenius Medical Care AG & Co. KGaA (Frankfurt FME / NYSE FMS) Investor RelationsElse-Kröner-Str. 161352 Bad Homburg v.d.H.

Oliver MaierHead of Investor Relations & Corp. Comm. Tel.: +49-(0)6172-609-2601 Fax.: +49-(0)6172-609-2301 E-mail: [email protected]

Gerrit Jost

Tel.: +49-(0)6172-609-5216 Fax.: +49-(0)6172-609-2301 E-mail: [email protected] Terry L. Morris

Tel.: +1-800-948-2538Fax.: +1-615-345-5605E-mail: [email protected]

More from Fresenius Medical Care AG & Co. KGaA

Regulatory Filings 2026
Jan 16
Share Issue/Capital Change 2026
Jan 12
Transaction in Own Shares 2026
Jan 9
Share Issue/Capital Change 2025
Dec 29
AGM Information 2025
Dec 22
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 15
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 12
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 8
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 3
Transaction in Own Shares 2025
Dec 1
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.